SIS
BBIO icon

Sound Income Strategies’s BridgeBio Pharma BBIO Stock Holding History

Sound Income Strategies’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-178
Closed -$13.3K – 657
2026
Q1 		$13.3K Hold
178
– – ﹤0.01% 1374
2025
Q4 		$13.6K Buy
+178
New +$11.7K ﹤0.01% 1310
2025
Q1 		– Sell
-100
Closed -$2.74K – 1565
2024
Q4 		$2.74K Hold
100
– – ﹤0.01% 1111
2024
Q3 		$2.55K Hold
100
– – ﹤0.01% 1084
2024
Q2 		$2.53K Buy
+100
New +$2.73K ﹤0.01% 1067

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Sound Income Strategies's BBIO Position: Q2 2026 in Review

Sound Income Strategies sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 178 shares — an estimated $13.3K sold.

Sound Income Strategies first reported a position in BBIO in Q2 2024 and held it in 5 quarters. The position peaked at $13.6K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Sound Income Strategies reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
  • Sound Income Strategies sold 178 BridgeBio Pharma shares in Q2 2026, an estimated $13.3K.
  • Sound Income Strategies first reported a position in BridgeBio Pharma in Q2 2024 and held it in 5 quarters.
  • Sound Income Strategies's BridgeBio Pharma position peaked at $13.6K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Sound Income Strategies's 13F filing for Q2 2026, filed 20 Jul 2026.